Please assess the completion status of the following clinical trial:

Trial Title: BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Male or female patients with age ≥18 years at screening.~* Have a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug.~* Have stable moderate to severe chronic plaque psoriasis with or without psoriatic arthritis at both Screening and Baseline (Randomisation):~  1. Have an involved body surface area (BSA) ≥10% and~ 2. Have a Psoriasis Area and Severity Index (PASI) score ≥12 and~ 3. Have a static Physician Global Assessment (sPGA) score of ≥3.~* Must be candidates for systemic therapy or phototherapy for psoriasis treatment, as assessed by the investigator.~* Must be a candidate for treatment with Stelara® (ustekinumab) according to local label.~Exclusion criteria:~* Patients with:~  1. non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular)~ 2. current drug-induced psoriasis (including an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)~ 3. active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis that might confound trial evaluations according to investigator's judgment~* Previous exposure to BI 655066.~* Previous exposure to ustekinumab (Stelara®).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Part A) (Type: PLACEBO_COMPARATOR): Participants randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
- Ustekinumab (Part A) (Type: ACTIVE_COMPARATOR): Participants randomized to receive double-blind (DB) ustekinumab 45 mg or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
- Risankizumab (Part A) (Type: EXPERIMENTAL): Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).

Based on this trial design, predict the completion outcome and termination type (if applicable).